Pasithea Therapeutics Corp. KTTAW
At closeSep 16, 2026, 4:49 PM EDT
After hours · Sep 16, 4:49 PM ET
- YTD
- -72.55%
- 1 year
- -72.55%
- Market cap
- 20.84K
- YTD return
- -72.55%
- 1-year return
- -72.55%
- Volume
- 383
- Open
- 0.0122
- Previous close
- 0.0028
- Day's range
- 0.0027 – 0.0028
- 52-week range
- 0.0027 – 0.0028
- Beta
- 0.82
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -9.02M
- Total cash
- 7.97M
- Total debt
- 0
- Return on equity
- -63.25%
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Consensus EPS estimate 0.00.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- pasithea.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on KTTAW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Kepos Capital Lp | 11.54% | 334,600 | 7.70K | Sep 29, 2024 |
| Warberg Asset Management LLC | 9.07% | 263,001 | 6.05K | Sep 29, 2024 |
| Armistice Capital, LLC | 1.72% | 50,000 | 1.15K | Sep 29, 2024 |
| Clear Street LLC | 0.00% | 100 | 2 | Sep 29, 2024 |